FILTRO MEDICAL INC.

San Jose, CA · Medtech · Private

Image-guided endovascular catheter-based filters that selectively bind and remove chemotherapy drugs from blood during intraarterial cancer treatment

Grants
$2.6M
4 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
2
0 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Endovascular ChemoFilter to Reduce Doxorubicin Toxicity during Intra-Arterial Chemotherapy$400,000
Federal grantDepartment of Health and Human Services · Phase II · Endovascular ChemoFilter to Reduce Doxorubicin Toxicity during Intra-Arterial Chemotherapy$199,664
Federal grantDepartment of Health and Human Services · Phase II · Endovascular ChemoFilter to Reduce Doxorubicin Toxicity during Intra-Arterial Chemotherapy$1,000,000
Federal grantDepartment of Health and Human Services · Phase II · Endovascular ChemoFilter to Reduce Doxorubicin Toxicity during Intra-Arterial Chemotherapy$1,000,000
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2160JELIKALITE LLC——
2161Regenexx, LLC—$10M
2162Moai Technologies L.L.C.——
2163FILTRO MEDICAL INC.——
2164NANOMAG LLC—$4.0M
2165Confer, LLC—$2.0M
2166BIOMEMBRETICS, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 2
  • Filtration Devices, And Systems And Methods For Using Themapplication
  • Filtration Devices, And Systems And Methods For Using Themapplication

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.